GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Delcath Systems Inc (NAS:DCTH) » Definitions » Net Margin %

Delcath Systems (Delcath Systems) Net Margin %

: -2,066.05% (As of Dec. 2023)
View and export this data going back to 2000. Start your Free Trial

Net margin is calculated as Net Income divided by its Revenue. Delcath Systems's Net Income for the three months ended in Dec. 2023 was $-11.14 Mil. Delcath Systems's Revenue for the three months ended in Dec. 2023 was $0.54 Mil. Therefore, Delcath Systems's net margin for the quarter that ended in Dec. 2023 was -2,066.05%.

The historical rank and industry rank for Delcath Systems's Net Margin % or its related term are showing as below:

DCTH' s Net Margin % Range Over the Past 10 Years
Min: -2308.86   Med: -1122.43   Max: -561.96
Current: -2308.86


DCTH's Net Margin % is ranked worse than
94.87% of 818 companies
in the Medical Devices & Instruments industry
Industry Median: 0.045 vs DCTH: -2308.86

Delcath Systems Net Margin % Historical Data

The historical data trend for Delcath Systems's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Delcath Systems Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Margin %
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -561.96 -1,467.56 -721.49 -1,342.70 -2,308.86

Delcath Systems Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Net Margin % Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1,325.82 -1,507.54 -1,454.95 -4,686.64 -2,066.05

Competitive Comparison

For the Medical Devices subindustry, Delcath Systems's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Delcath Systems Net Margin % Distribution

For the Medical Devices & Instruments industry and Healthcare sector, Delcath Systems's Net Margin % distribution charts can be found below:

* The bar in red indicates where Delcath Systems's Net Margin % falls into.



Delcath Systems Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Delcath Systems's Net Margin for the fiscal year that ended in Dec. 2023 is calculated as

Net Margin=Net Income (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=-47.678/2.065
=-2,308.86 %

Delcath Systems's Net Margin for the quarter that ended in Dec. 2023 is calculated as

Net Margin=Net Income (Q: Dec. 2023 )/Revenue (Q: Dec. 2023 )
=-11.136/0.539
=-2,066.05 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Delcath Systems  (NAS:DCTH) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.


Delcath Systems Net Margin % Related Terms

Thank you for viewing the detailed overview of Delcath Systems's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Delcath Systems (Delcath Systems) Business Description

Traded in Other Exchanges
Address
1633 Broadway, Suite 22C, New York, NY, USA, 10019
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product candidate, Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System, or Melphalan/HDS, is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.
Executives
Vojo Vukovic officer: See Remarks C/O SYNTA PHARMACEUTICALS CORP., 45 HARTWELL AVENUE, LEXINGTON MA 02421
Gerard J Michel director, officer: Chief Executive Officer 420 CHIPETA WAY, SALT LAKE CITY UT 84108
Sandra Pennell officer: See Remarks C/O VERICEL CORPORATION, 64 SIDNEY STREET, CAMBRIDGE MA 02139
David L. Hoffman officer: See Remarks C/O DELCATH SYSTEMS, INC., 1633 BROADWAY, SUITE 22C, NEW YORK NY 10019
John Purpura officer: EVP, Regulatory Affairs 600 FIFTH AVENUE, 23RD FLOOR, NEW YORK NY 10020
John Richard Sylvester director C/O DELCATH SYSTEMS, INC., 1633 BROADWAY, SUITE 22C, NEW YORK NY 10019
Salamon Steven A J director 25 ADMIRAL ROAD, TORONTO A6 M5R 2L4
Rosalind Advisors, Inc. director, other: See Remarks 15 WELLESLEY STREET WEST, SUITE 326, TORONTO A6 M4Y 0G7
Kevin Muir officer: See Remarks C/O DELCATH SYSTEMS, INC., 1633 BROADWAY, SUITE 22C, NEW YORK NY 10019
Anthony Dias officer: Vice President of Finance C/O SEACHANGE INTERNATIONAL, 50 NAGOG PARK, ACTON MA 01720
Gil Aharon director 15 WELLESLEY STREET WEST, SUITE 326, TORONTO A6 M4Y 0G7
Johnny John officer: See Remarks C/O DELCATH SYSTEMS, INC., 1633 BROADWAY, SUITE 22C, NEW YORK NY 10019
Elizabeth Czerepak director 201 ROUTE 17 NORTH, RUTHERFORD NJ 07070
Christine Padula officer: See Remarks C/O DELCATH SYSTEMS, INC., 1633 BROADWAY, SUITE 22C, NEW YORK NY 10019
Simon Pedder director 1001 MAIN STREET, SUITE 600, BUFFALO NY 14203